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Abstract
Rationale: Despite awareness of chronic obstructive pulmonary
disease (COPD) treatment recommendations, uptake is poor. The
Subpopulations and Intermediate Outcome Measures in COPD
Study (SPIROMICS) spans 2010–2016, providing an opportunity
to assess integration of 2011 Global Initiative for Obstructive
Lung Disease (GOLD) treatment strategies over time in a large
observational cohort study.
Objectives: To evaluate how COPD treatment aligns with 2011
GOLD strategies and determine factors associated with failure to
align with recommendations.
Methods: Information on inhaled medication use collected via
questionnaire annually for 4 years was compiled into therapeutic
classes (long-acting antimuscarinic agent, long-acting b-agonist,
inhaled corticosteroids [ICS], and combinations thereof).
Medications were not modified by SPIROMICS investigators. 2011
GOLD COPD categories A, B, C, and D were assigned. Alignment of
inhaler regimen with first-/second-line GOLD recommendations
was determined, stratifying into recommendation aligned or
nonaligned. Recommendation-nonaligned participants were further
stratified into overuse and underuse categories.
Results: Of 1,721 participants with COPD, at baseline, 52%
of regimens aligned with GOLD recommendations. Among
participants with nonaligned regimens, 46% reported underuse,
predominately owing to lack of long-acting inhalers in GOLD
category D. Of the 54% reporting overuse, 95% were treated with
nonindicated ICS-containing regimens. Among 431 participants with
4 years of follow-up data, recommendation alignment did not change
over time. When we compared 2011 and 2017 recommendations, we
found that 47% did not align with either set of recommendations,
whereas 35% were in alignment with both recommendations.
Conclusions: Among SPIROMICS participants with COPD,
nearly 50% reported inhaler regimens that did not align with GOLD
recommendations. Nonalignment was driven largely by overuse of
ICS regimens in milder disease and lack of long-acting inhalers in
severe disease.
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Chronic obstructive pulmonary disease
(COPD) treatment recommendations are
available to assist clinicians with selection
of pharmacological therapy in COPD,
but overall adherence to guideline
recommendations remains limited (1, 2).
The most widely used therapeutic strategy
is proposed by the Global Initiative for
Chronic Obstructive Lung Disease (GOLD).
This treatment strategy was initially
published in 2001, with updates in 2011 and
most recently in 2018 (3–5). Despite the
ubiquity of the GOLD treatment strategy,
small observational studies report poor
uptake of GOLD recommendations
worldwide, with some studies
demonstrating more than 50% of patients
with COPD reporting treatments not
consistent with guideline recommendations
(1, 6–12). There is little information on how
alignment with treatment recommendations
changes over time or on factors associated
with overuse and underuse. Identifying and
describing patient populations who are
receiving suboptimal medication regimens
can improve uptake of published treatment
recommendations and overall COPD care.
The Subpopulations and Intermediate
Outcome Measures in COPD Study
(SPIROMICS) is a large, multicenter,
observational cohort study of current and
former smokers with extensive data
regarding physiologic status, clinical
parameters, and medication use (13).
SPIROMICS collected data from 2010
through 2016, permitting a unique
opportunity to analyze associations between
demographic factors and alignment
with treatment recommendations, as
well as how this alignment changed over
time. Given 2011 GOLD treatment
strategies (5) were used as the standard
for diagnosis and management of COPD at
the time of SPIROMICS data collection,
the present analysis examines the alignment
of medication use in SPIROMICS with
2011 GOLD recommendations. Some
of the results of these studies were




SPIROMICS is a multicenter cohort study
with recruitment from 12 clinical centers
and including former and current smokers
(.20 pack-years) with and without COPD
and nonsmoking control subjects (13).
Participant recruitment occurred through
referrals from physicians at each clinical
center, community-based recruitment in
locations where individuals were seeking
medical care (i.e., doctors’ offices,
pulmonary rehabilitation clinics), or self-
referrals. The analytical cohort for this study
is limited to SPIROMICS participants
with spirometry-defined COPD at the time
of SPIROMICS visit (defined as post-
bronchodilator ratio of forced expiratory
volume in 1 s [FEV1] to forced vital capacity
[FVC] ,0.70) with complete 2011 GOLD
categorization (5) and medication use
data at the baseline visit. All participants
provided written informed consent, and
institutional review boards at each
Table 1. Alignment of inhaler therapies with Global Initiative for Chronic Obstructive Lung Disease recommendations
GOLD
Category
First-/Second-Line Therapy Underuse Overuse
A SAMA as needed or SABA as needed
or LAMA or LABA or SABA1 SAMA
N/A ICS monotherapy or ICS1 LABA
or ICS1 or LAMA1 LABA or
ICS1 LAMA1 LABA
B LAMA or LABA or LAMA1 LABA No inhaler or ICS monotherapy ICS1 LABA or ICS1 LAMA or
ICS1 LAMA1 LABA
C ICS1 LABA or LAMA or LAMA1 LABA No inhaler or LABA monotherapy
or ICS monotherapy
LAMA1 ICS or ICS1 LAMA1 LABA
D ICS1 LABA or LAMA or ICS1 LAMA or
ICS1 LABA1 LAMA or LAMA1 LABA
No inhaler or LABA monotherapy
or ICS monotherapy
N/A
Definition of abbreviations: GOLD =Global Initiative for Chronic Obstructive Lung Disease; ICS = inhaled corticosteroid; LABA = long-acting b-agonist;
LAMA = long-acting antimuscarinic agent; N/A = not applicable; SABA = short-acting b-agonist; SAMA = short-acting muscarinic antagonist.
Bold regimens are first-choice inhaler regimens. Italicized regimens are second-choice inhaler regimens.
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SPIROMICS clinical center approved the
study.
Data Collection
SPIROMICS participants were followed for
up to 3 years with annual visits (baseline
plus up to three annual follow-up visits).
All SPIROMICS baseline and follow-up
questionnaires are publicly available from
www.spiromics.org. Data on demographics,
smoking status and history, inhaler
medication use, and COPD exacerbation
occurrence were obtained via self-report at
each visit. COPD exacerbations included
any respiratory flare-up requiring healthcare
use involving the use of antibiotics or
systemic corticosteroids or both in the prior
12 months (15). History of emphysema,
asthma, chronic bronchitis, and COPD was
defined at baseline via self-report of ever
having received a physician diagnosis.
Measurements collected at each visit
included pre- and post-bronchodilator
spirometry as well as respiratory
assessments, including the modifiedMedical
Research Council dyspnea scale (mMRC)
(16) and the COPD Assessment Tool (CAT)
(17). Analyses were completed using
spirometry from the baseline visit.
Medication use was assessed via a
questionnaire asking, “[I]n the past
3 months, have you used.” a class of
medication including inhaled steroids,
inhaled bronchodilators, nebulized
bronchodilators, and other oral
medications. Medications were not modified
by SPIROMICS investigators. Each category
of inhaled drug was then followed by specific
brand names and dosages for participants to
select. At each visit, participants were
assigned GOLD categorizations of A, B, C,
or D based on 2011 guidelines using
exacerbations, airflow obstruction, and
symptom burden. Symptom scores using
the CAT were used for categorization as
recommended by guidelines (5).
For the purpose of analysis, alignment
with treatment recommendations at each
visit was defined as alignment of the
participant’s prescribed regimen to
either first- or second-line GOLD
recommendations of inhaled medications
only (Table 1). For GOLD-A, first-line
therapy was as-needed use of short-acting
anticholinergic agents (SAMA) or short-
acting b-agonists (SABA). First-line
pharmacologic therapy for GOLD-B
Table 2. Baseline demographics
Full Cohort GOLD A GOLD B GOLD C GOLD D
No. of subjects 1,721 383 (22) 665 (39) 75 (4) 598 (35)
Age, yr 65.2 (8.0) 67.7 (7.3) 64.8 (8.2) 67.3 (7.4) 63.8 (7.9)
Male sex, n (%) 995 (58) 125 (33) 297 (45) 44 (59) 325 (54)
Race, n (%)
White 1,401 (81) 324 (85) 547 (82) 61 (81) 469 (78)
Black 259 (15) 44 (11) 94 (14) 13 (17) 108 (18)
Other/missing 61 (4) 15 (4) 24 (4) 1 (1) 21 (3)
Current smoker, n (%) 579 (34) 99 (26) 297 (45) 14 (19) 169 (29)
Pack-years, median (Q1–Q3) 46 (35–62) 45 (33–59) 47 (38–66) 43 (35–60) 49 (35–63)
FEV1/FVC, post-BD 0.51 (0.13) 0.59 (0.08) 0.57 (0.09) 0.43 (0.11) 0.40 (0.12)
FEV1, post-BD
Absolute, L 1.73 (0.77) 2.30 (0.69) 2.03 (0.61) 1.22 (0.48) 1.10 (0.47)
Percent predicted 60.6 (23) 78.8 (16) 71.3 (15) 44.6 (16) 39.0 (15)
FVC, post-BD
Absolute, L 3.34 (1.05) 3.88 (0.99) 3.55 (0.98) 2.91 (1.03) 2.81 (0.91)
Percent predicted 88.4 (20) 100 (16) 94.7 (16) 78.7 (20) 75.1 (18)
GOLD FEV1 stratum, n (%)
I 364 (21) 176 (46) 170 (26) 4 (5) 14 (2)
II 772 (45) 207 (54) 495 (75) 7 (9) 63 (11)
III 413 (24) 0 (0) 0 (0) 55 (73) 358 (60)
IV 172 (10) 0 (0) 0 (0) 9 (12) 163 (27)
Exacerbations in prior year, n (%)
None 1,192 (70) 340 (90) 526 (80) 45 (61) 281 (47)
One 304 (18) 37 (10) 131 (20) 11 (15) 125 (21)
Two or more 206 (12) 0 (0) 0 (0) 18 (24) 188 (32)
CAT score
Median (Q1–Q3) 15 (9–21) 6 (4–8) 17 (13–22) 7 (5–8) 20 (15–24)
>10, n (%) 1,263 (73) 0 (0) 665 (100) 0 (0) 598 (100)
mMRC score
Median (Q1–Q3) 1 (1–2) 0 (0–1) 1 (1–2) 1 (1–1) 2 (1–3)
>2, n (%) 559 (32) 17 (4) 195 (29) 13 (17) 334 (56)
Self-reported, n (%)
COPD 1,283 (77) 180 (51) 494 (77) 62 (85) 547 (95)
CB 438 (27) 49 (13) 156 (25) 17 (24) 216 (39)
Emphysema 814 (50) 104 (29) 276 (45) 43 (59) 391 (69)
COPD, CB, or emphysema 1,402 (81) 220 (57) 544 (82) 68 (91) 570 (95)
Asthma 388 (23) 52 (14) 158 (24) 18 (24) 160 (27)
Definition of abbreviations: BD = bronchodilator; CAT = COPD Assessment Test; CB = chronic bronchitis; COPD= chronic obstructive pulmonary disease;
FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity; GOLD =Global Initiative for Chronic Obstructive Lung Disease; mMRC =modified
Medical Research Council dyspnea scale.
All values are mean (standard deviation) unless otherwise indicated.
ORIGINAL RESEARCH
202 AnnalsATS Volume 16 Number 2| February 2019
 
participants was a long-acting antimuscarinic
agents (LAMA) or a long-acting b-agonist
(LABA). GOLD-C first-line therapy was
either a LAMA or a combination of an
inhaled corticosteroid (ICS) and a LABA.
GOLD-D first-line therapy was either a
LAMA or a combination of an ICS and
a LABA. Second-line therapies are
summarized in Table 1. Nonalignment with
GOLD recommendations was defined as
participants’ inhaler regimens that did not fit
within first- or second-line recommendations
based on GOLD categorization.
Recommendation-nonaligned
participants were further stratified into
overuse and underuse on the basis of
maintenance inhaler use as outlined in
Table 1. Underuse was defined as use of less
medication than allotted for a specific
GOLD class. GOLD-B participants were
defined as reporting underuse if they lacked
long-acting maintenance therapy, such
as LAMA or LABA, or lacked long-acting
maintenance therapy, such as LAMA or
LABA. For GOLD-B participants, use of ICS
monotherapy was categorized as underuse.
Both GOLD-C and GOLD-D underuse was
defined by no maintenance therapy or use
of LABA or ICS monotherapy. Overuse was
defined as use of more medications than
recommended for a specific GOLD
classification. For GOLD-A, overuse included
treatment with any ICS, combination ICS and
LABA, combination of ICS and LAMA,
combination of LAMA and LABA, or LAMA/
LABA/ICS therapy. GOLD-B overuse
included treatment with any ICS-containing
regimen (excluding ICS monotherapy,
because this was classified as underuse). For
GOLD-C participants, overuse was defined as
combination of LAMA and ICS or use of
LAMA/LABA/ICS. Analyses were conducted
to examine the impact of income, education,
and prior history of physician-diagnosed
asthma on alignment with GOLD
recommendations. Secondary analysis
of alignment with 2017 GOLD
recommendations was also conducted.
Statistical Methods
Baseline differences in demographic and
clinical factors between cohort participants,
stratified by alignment with recommendations,
were assessed using chi-square tests
(categorical variables) or analysis of
variance (ANOVA) (continuous
variables). Differences in medication
use patterns at baseline, stratified by
alignment and by treatment, were assessed
via chi-square tests using Fisher’s exact
test to account for low frequency counts.
Change in alignment over time was
assessed among participants with
complete follow-up data with the
‘PTREND’ STATA module, calculating
chi-square test results for departure from
the trend line of alignment over visits. To
reduce the risk of type I error related to
multiple comparisons, a Bonferroni-
corrected P value less than 0.002 (derived
from the largest set of simultaneous
comparisons [n = 22]) was used to define
statistical significance in all comparisons.




The total SPIROMICS cohort (N = 2,974)
included 1,831 individuals with spirometry-
confirmed COPD (FEV1/FVC, ,0.7). The
analytical cohort in the present study
included 1,721 participants with spirometry-
confirmed COPD and complete baseline
medication use and 2011 GOLD
categorization data, representing 94% of
participants with COPD in SPIROMICS (see
Figure E1 in the online supplement). The
average age was 65.2 years; 58% were male;
81% were white; and 34% were current
smokers (Table 2). At baseline, 22% of
participants were classified as GOLD-A, 39%
as GOLD-B, 4% as GOLD-C, and 35% as
GOLD-D. Distribution of race was similar
among GOLD categories; however, all other
demographic and clinical characteristics were
different among GOLD categories. GOLD-A
participants were oldest (67.76 7.3 yr),
whereas GOLD-D participants were
youngest (63.86 7.9 yr). GOLD-A
participants had the highest proportion of
women (67%), whereas GOLD-C had the
lowest proportion of women (41%). The
GOLD-B cohort had the highest prevalence
of current smokers (45%), whereas GOLD-C
had the lowest prevalence of current smokers
(19%). Lung function was lowest in GOLD-D
(FEV1 percent predicted, 396 15%) and
highest in GOLD-A (FEV1 percent predicted,
78.86 16%). Of the total cohort, 66% had
mild to moderate airflow obstruction. As
expected, higher proportions of GOLD-A
and GOLD-B participants (90% and 80%,
respectively) than GOLD-C and GOLD-D
participants (61% and 47%, respectively) had
no exacerbations. Of the total cohort, 81%
reported having a physician diagnosis of
either COPD, chronic bronchitis, or COPD,
with GOLD-D participants being most likely
to report any of these diagnoses. Only 57% of
GOLD-A participants reported a diagnosis
of either COPD, chronic bronchitis, or
emphysema.
Baseline medication use is summarized
in Figure E2 and Table E1. At baseline, 27%
of the entire cohort reported not using any
inhaler (short-acting or maintenance),
whereas 37% reported no long-acting
maintenance inhaler use. The most
prevalent maintenance inhaler use among
GOLD-A and GOLD-B participants was a
combination of LABA/ICS (10% and 20%,
respectively), whereas triple therapy with
100
Proportion of SPIROMICS Participants Aligning with













Total GOLD A GOLD B GOLD C GOLD D
Figure 1. Proportion of Subpopulations and Intermediate Outcome Measures in COPD Study
(SPIROMICS) participants aligning with Global Initiative for Chronic Obstructive Lung Disease (GOLD)
first- or second-line treatment recommendations, stratified by baseline GOLD group.
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LAMA/LABA/ICS was the most common in
GOLD-C and GOLD-D participants (37%
and 43%, respectively). Of the total cohort,
4% reported ICS monotherapy as their only
maintenance inhaler. Oral glucocorticoid
use was uncommon in the cohort (4%), with
increasing use in GOLD-C and GOLD-D
participants. Specifically, glucocorticoid
use was reported in 0.5% of GOLD-A
participants, 1% of GOLD-B participants,
5% of GOLD-C participants, and 8% of
GOLD-D participants.
Overall Alignment with 2011
GOLD Recommendations
At baseline, only 52% of overall participants’
regimens aligned with GOLD first-/second-
line treatment recommendations (Figure 1),
with lowest alignment in GOLD-B (14%)
and GOLD-C (33%). Highest alignment
with recommendations was among
GOLD-A and GOLD-D (77% and 80%,
respectively) in the overall cohort. As seen in
Table 3, age, sex, and race did not differ
between participants whose treatment
aligned with GOLD recommendations
compared with those whose treatment did
not. Participants with regimens not aligning
with recommendations had better lung
function (FEV1 percent predicted, 66% vs.
56%; FVC percent predicted 92% vs. 85%;
P, 0.01 for both comparisons). These
participants were also more likely to be
current smokers (41% vs. 28%; P, 0.001)
and to report no exacerbations in the prior
12 months (78% vs. 63%; P, 0.001).
Participants with regimens not aligning with
recommendations reported less severe
dyspnea (mMRC score >2; 29% vs. 35%)
but worse overall COPD control (CAT score
>10; 83% vs. 64%). There was no difference
in self-report of either COPD, chronic
bronchitis, or emphysema. Baseline
maintenance inhaler use among the 833
participants with regimens not aligning with
GOLD recommendations is summarized in
Figure E3 and Table E2. A total of 29%
reported no short-acting or maintenance
inhalers, and 45% reported no maintenance
inhaler use. The most prevalent regimen
of both GOLD-A and GOLD-B
recommendation–nonaligned participants
was LABA/ICS (45% and 23%, respectively).
The most prevalent regimen of GOLD-C
recommendation–nonaligned participants
was LAMA/LABA/ICS (56%). Among
nonaligned GOLD-D participants, 73%
reported no maintenance inhaler use, with
19% reporting LABA monotherapy use.
There was a wide range of alignment across
the 13 study sites, ranging from 33% to 69%.
This difference, when assessed by ANOVA,
was not statistically different (P = 0.91).
Underuse versus Overuse
Among participants whose treatment did
not align with recommendations, 449 (54%)
were due to underuse and 384 (46%)
were due to overuse (Figure 2). Among
nonaligned participants, overuse was seen in
100% of GOLD-A participants, 46% of
GOLD-B participants, 60% of GOLD-C
participants, and 0% of GOLD-D
participants. Sex and race were similar
between those reporting underuse versus
those reporting overuse (Table 4).
Compared with the overuse group, members
of the underuse group were more likely to be
current smokers (49% vs. 31%; P, 0.001)
and to have a greater proportion with severe
obstruction as measured by FEV1 (GOLD
FEV1 strata III/IV) (27% vs. 7%; P, 0.001).
Participants with underuse also had worse








No. of subjects 888 833
Age, yr 65.5 (7.8) 64.9 (8.2) 0.11
Male sex, n (%) 524 (59) 471 (57) 0.30
Race, n (%) 0.22
White 736 (83) 665 (80)
Black 125 (14) 134 (16)
Other/missing 27 (3) 34 (4)
Current smoker, n (%) 246 (28) 333 (41) ,0.001
Pack-years, median (Q1–Q3) 46 (35–62) 45 (36–63) ,0.001
FEV1/FVC, post-BD 0.48 (0.14) 0.54 (0.11) ,0.001
FEV1, post-BD
Absolute, L 1.61 (0.82) 1.86 (0.69) ,0.001
Percent predicted 55.9 (25) 65.5 (19) ,0.001
FVC, post-BD
Absolute, L 3.26 (1.09) 3.42 (1.01) 0.002
Percent predicted 85.4 (21) 91.5 (19) ,0.001
GOLD FEV1 stratum, n (%)
I 182 (21) 182 (22)
II 269 (30) 503 (60)
III 298 (34) 115 (14)
IV 139 (16) 33 (4) ,0.001
GOLD category, n (%)
A 295 (33) 88 (11)
B 90 (10) 575 (69)
C 25 (3) 50 (6)
D 478 (54) 120 (14) ,0.001
Exacerbations in prior year, n (%)
None 553 (63) 639 (78)
One 159 (18) 145 (18)
Two or more 166 (19) 40 (5) ,0.001
CAT score
Median (Q1–Q3) 14 (7–21) 16 (11–21) ,0.001
>10, n (%) 568 (64) 695 (83) ,0.001
mMRC score
Median (Q1–Q3) 1 (0–2) 1 (1–2) ,0.001
>2, n (%) 315 (35) 244 (29) 0.006
Self-reported, n (%)
COPD 662 (77) 621 (77) 0.96
CB 246 (30) 192 (25) 0.09
Emphysema 465 (55) 349 (45) ,0.001
COPD, CB, or emphysema 719 (81) 683 (82) 0.59
Asthma 184 (21) 204 (25) 0.03
Definition of abbreviations: BD = bronchodilator; CAT = COPD Assessment Test; CB = chronic
bronchitis; COPD = chronic obstructive pulmonary disease; FEV1 = forced expiratory volume in
1 second; FVC = forced vital capacity; GOLD =Global Initiative for Chronic Obstructive Lung Disease;
mMRC=modified Medical Research Council dyspnea scale.
All values are mean (standard deviation) unless otherwise indicated.
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overall symptom control, defined as
CAT score greater than or equal to 10 (96%
vs. 69%; P, 0.001), despite a similar
proportion with mMRC score greater than or
equal to 2 (30% vs. 29%; P = 0.82), and a
higher proportion had two or more
exacerbations in the year before baseline visit
(7% vs. 2%; P, 0.001). Given the increased
symptoms and exacerbations, participants
with underuse were also more likely to be
classified as GOLD-C or GOLD-D (30%
vs. 8%; P, 0.001). The underuse group was
less likely to report a diagnosis of either
COPD, chronic bronchitis, or emphysema
(72% vs. 93%; P, 0.001) as well as asthma
(19% vs. 32%; P, 0.001).
Underuse was predominately driven
by no long-acting inhaler (83%), followed
by ICS monotherapy (14%) (Table E3).
Inappropriate ICS-containing inhalers
accounted for all of those classified with
overuse in the recommendation-nonaligned
participants, most commonly LAMA/
LABA/ICS (48%). When we compared the
distribution of overuse and underuse among
the nonaligned group, we again found a
wide range of overuse across sites (0–63%),
with no statistical difference by site observed
by ANOVA (P = 0.26).
Change in Alignment with GOLD
Recommendations over Time
A total of 431 participants (25% of the
analytical cohort) had complete follow-up
data for GOLD categorization and
medication use. There were no substantial
differences in baseline demographics and
medication use between those with and
without complete follow-up data (Tables E4
and E5). Average alignment with GOLD
recommendations forGOLD-A andGOLD-D
participantswas 76%at the baseline visit, and it
didnot changewithupdatedGOLDstatus in
subsequent years (P = 0.72 and P = 0.52,
respectively) (Figure 3 and Table E6). Both
GOLD-B and GOLD-C participants had a
statistically nonsignificant but numerical
increase in alignment over time (GOLD-B,
10–17%; GOLD-C, 36–55%).
Sensitivity Analysis
Ever reporting physician-diagnosed asthma
was associated with greater nonalignment to
recommendations (53% vs. 46%; P = 0.034).
History of asthma in this COPD cohort was
associated with greater prevalence of
overuse than among participants without
asthma (58% vs. 41%; P, 0.001). Among
participants with overuse reporting asthma,
51% reported LABA/ICS use, whereas 38%
reported LAMA/LABA/ICS use. This
contrasts with the participants with COPD
without asthma, in whom the most common
regimen was LAMA/LABA/ICS (53%),
followed by LABA/ICS (41%). The overall
use of an ICS-containing regimen did not
differ between participants with COPD with
or without asthma (P = 0.47).
Among participants whose treatment
did not align with recommendations, lower
income was associated with underuse.
Specifically, 59% of participants with annual
income less than $35,000 reported underuse
compared with 51% of participants with
annual income of $35,000 or higher
(P = 0.027). Similar trends were seen
with an income threshold of $50,000
(P = 0.05). There was no difference in
alignment with recommendations when
stratified by attained education level
(P = 0.316). In addition, in the participants
whose treatment did not align with
recommendations, there was no difference of
education level for overuse or underuse.
When we compared GOLD
categorization between 2011 and 2017
publications, we observed that 72% of
participants remained within the same
GOLD category between the two definitions.
The most substantial reclassification
was among the 598 GOLD-D (2011)
participants, with 406 (68%) reclassified as
GOLD-B using 2017 criteria. When we
compared alignment with GOLD 2011 and
2017 treatment recommendations, we
observed that 47% did not align with either
2011 or 2017 treatment recommendations,
whereas 35% aligned with both
recommendations. Only 27 participants
(2%) aligned with 2017 recommendations
but not 2011 recommendations. A total
of 289 participants (17%) had regimens
aligned with 2011 recommendations but
not 2017 recommendations. Of these 289
participants, 98% reported overuse per 2017
recommendations. This was due to
reclassification from GOLD-C/D to GOLD-
A/B owing to removal of FEV1 criteria.
Discussion
In this analysis of a large cohort of
individuals with COPD participating in
an observational cohort study, nearly 50%
reported inhaler regimens that do not align
with first- or second-line recommendations
present at the timeofdata collection.Regimens
not aligning with GOLD recommendations
were evenly split between overuse and
underuse. Underuse was primarily due to lack
of maintenance inhalers, whereas overuse was
due to inappropriate use of ICS-containing
regimens. Aside from GOLD-B participants,
overall alignment with recommendations did
not change during follow-up. These findings
highlight the lack of substantial uptake of
published recommendations and the relatively
stable treatment patterns for COPD over time.
The GOLD recommendations are















Overuse and underuse among SPIROMICS participants
not aligning with GOLD recommendations
GOLD A GOLD B GOLD C GOLD D
Overuse Underuse
Figure 2. Distribution of overuse and underuse among Subpopulations and Intermediate Outcome
Measures in COPD Study (SPIROMICS) participants not aligning with Global Initiative for Chronic
Obstructive Lung Disease (GOLD) first- or second-line treatment recommendations, stratified by
baseline GOLD group.
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for COPD diagnosis and treatment. Despite
this ubiquity, nonadherence to both
diagnostic and treatment recommendations
are prevalent (1, 6, 7, 9). Prior studies have
identified some barriers to poor uptake,
including provider familiarity and time
constraints (8, 18). To our knowledge, this is
one of the largest analyses examining factors
associated with overuse and underuse in a
well-characterized COPD population, as
well as the largest to examine change in
alignment with recommendations over
time. We found that alignment with
recommendations was largely unchanged
from reports examining 2007 GOLD
guidelines (7), despite increased awareness
and publications surrounding the GOLD
recommendations over the last decade.
GOLD-B and GOLD-C participants
had the highest rates of recommendation
nonalignment. Prior studies have suggested
that the complexity of GOLD assessments
may impact alignmentwith recommendations
(19). Using the 2011 GOLD guidelines,
classification into a group requires both
spirometry and symptoms. Spirometry is
frequently not obtained (8), which may
lead to misclassification. Although all
SPIROMICS participants underwent
spirometry within the context of research
visits, providers prescribing inhalers may
not have obtained spirometry. In addition,
the 2011 recommendations did not include
guidance on stepping up or stepping down
therapy, which may have led to persistent
nonalignment with treatment strategies (20).
Among the participants not aligning
with recommendations, those who reported
underuse were more likely to have more
severe obstruction (GOLD III/IV), be more
symptomatic, and have a higher proportion
of COPD exacerbations. The association
between underuse and more severe disease
burden has several potential explanations.
Those with underuse were less likely to
report a diagnosis of obstructive lung
disease, raising the possibility that these
patients either were not being diagnosed
or were not aware of their diagnoses.
Alternatively, the higher burden of
symptoms and exacerbations among these
participants may be underrecognized by
providers, therefore leading to underuse.
Without use of objective scales, physicians
are frequently unable to properly identify
symptoms most affecting their patients (21).
Participants reporting underuse were more
likely to be current smokers, so providers
may have attributed symptoms to smoking
rather than to COPD. Similarly to other
studies (7, 10), the majority of participants
with underuse lacked maintenance inhalers.
Moreover, nearly one-third of these
participants did not report any inhaler use
(either short or long acting). The lowest
income group was associated with underuse,
suggesting that medication cost may
contribute to nonalignment with published
treatment strategies. These findings differ
from those of Nishi and colleagues, who
observed that patients with COPD with dual
eligibility for Medicare and Medicaid are
more likely to use maintenance inhalers,
likely owing to a reduced copay burden (22).
SPIROMICS did not capture insurance
status, limiting the ability to determine how
this factor may be impacting alignment with
guidelines. These symptomatic participants
reporting underuse highlight a group
that, if appropriately treated, could have
improvement of symptom burden.
Participants reporting overuse were
more likely to have mild obstruction




No. of subjects 449 384
Age, yr 64.4 (8.3) 65.5 (8.0) 0.05
Male sex, n (%) 260 (58) 211 (55) 0.39
Race, n (%) 0.47
White 360 (80) 305 (79)
Black 68 (15) 66 (17)
Other/missing 21 (5) 13 (4)
Current smoker, n (%) 216 (49) 117 (31) ,0.001
Pack-years, median (Q1–Q3) 49 (38–63) 45 (35–61) 0.09
FEV1/FVC, post-BD 0.54 (0.12) 0.54 (0.10) 0.88
FEV1, post-BD
Absolute, L 1.87 (0.75) 1.84 (0.60) 0.53
Percent predicted 65.2 (22) 65.8 (15) 0.67
FVC, post-BD
Absolute, L 3.43 (1.06) 3.42 (0.95) 0.85
Percent predicted 90.5 (20) 92.8 (17) 0.08
GOLD FEV1 stratum, n (%)
I 118 (26) 64 (17)
II 210 (47) 293 (76)
III 93 (21) 22 (6)
IV 28 (6) 5 (1) ,0.001
GOLD category, n (%)
A 0 (0) 88 (23)
B 309 (69) 266 (69)
C 20 (4) 30 (8)
D 120 (26) 0 (0) ,0.001
Exacerbations in prior year, n (%)
None 353 (80) 286 (76)
One 60 (13) 85 (22)
Two or more 33 (7) 7 (2) ,0.001
CAT score
Median (Q1–Q3) 17 (12–22) 14 (8–20) ,0.001
>10, n (%) 429 (96) 266 (69) ,0.001
mMRC score
Median (Q1–Q3) 1 (1–2) 1 (1–2) 0.94
>2, n (%) 133 (30) 111 (29) 0.82
Self-reported, n (%)
COPD 279 (65) 342 (92) ,0.001
CB 85 (20) 107 (30) 0.003
Emphysema 162 (39) 187 (52) 0.002
COPD, CB, or emphysema 324 (72) 359 (93) ,0.001
Asthma 85 (19) 119 (32) ,0.001
Definition of abbreviations: BD = bronchodilator; CAT = COPD Assessment Test; CB = chronic
bronchitis; COPD = chronic obstructive pulmonary disease; FEV1 = forced expiratory volume in
1 second; FVC = forced vital capacity; GOLD =Global Initiative for Chronic Obstructive Lung Disease;
mMRC=modified Medical Research Council dyspnea scale.
All values are mean (standard deviation) unless otherwise indicated.
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(GOLD I/II), and all were on an ICS-containing
regimen. ICS-containing regimens in COPD
are indicated for GOLD-C or GOLD-D
COPD (4, 5). A recent analysis has shown
that more than one-third of those classified
as GOLD-A and over half of those classified
as GOLD-B for inhaler therapy are
inappropriately prescribed ICS regimens
(23). In that analysis, ICS/LABA therapy
was the initial treatment choice for over 50%
of patients. Similarly, we found that over
50% of all participants were prescribed ICS-
containing regimens, and 92% of overuse
participants were in GOLD-A or GOLD-B.
Given the prevalence of asthma in this group
with overuse, the ICS inhaler regimens may
reflect treatment for asthma or asthma–
COPD overlap. The treatment paradigm
for asthma–COPD overlap has yet to be
elucidated (24). The overall use of ICS
did not differ between the overusing
participants with and without asthma, and
it remains unclear if ICS could be an
appropriate treatment for these participants.
Another reason for overuse with ICS may
be related to combination medication
availability. For the first two years of this
study, ICS/LABA combined inhalers were
the only long-acting combination inhalers
available (25). Nevertheless, although
overuse may provide symptomatic benefits,
therapies are not risk free, because there are
many known side effects of ICS, including
thrush and increased risk of pneumonia (26).
Among the 25% of the analytical cohort
with complete follow-up data, failure to
align with recommendations was largely
stable over the duration of follow-up in
SPIROMICS. Given that there were no
guidelines for stepping down therapy in
2011, many overuse participants may have
been stepped up to achieve disease control
and, once adequately controlled on ICS, may
have been recategorized as GOLD-A or
GOLD-B with overuse due to ICS therapy.
In our analysis, patients with overuse were
less symptomatic, which may dissuade
practitioners from stepping down therapy
once symptoms are controlled. Prior studies
have described inertia among healthcare
providers regarding changing current
practices (27). A recent audit evaluating
treatment of COPD in outpatient settings
showed that at follow-up visits, providers
are most likely to keep the current regimen
(64.8%) or step-up therapy (17.5%), whereas
only 9.7% of visits involved stepped-down
therapy (20). A smaller study in Hong Kong
showed that over three visits, less than
one-third of patients had changes in
pharmacologic therapy, and the primary
reason for change was insufficient disease
control (10).
This study has several limitations. Data
collection for exacerbations, smoking
history, and medication use were obtained
via self-report, increasing the chance for
information and recall bias. Medication
prescriptions were not verified with
pharmacy records. Participants’ accuracy of
reporting medications may have increased
over serial study visits (Hawthorne effect).
In addition, there are no data on the type of
providers, difference in prescribing practices
among pulmonologists and primary care
physicians, appropriate inhaler technique,
and influence of pharmaceutical marketing
forces, all of which may impact alignment
with treatment recommendations. The
GOLD recommendations, although widely
cited and used to inform treatment, are
limited in the strength of evidence supporting
some treatment recommendations (5).
Although our analysis was not designed
to assess the validity of GOLD
recommendations, the degree of uncertainty
in some GOLD recommendations is a
limitation impacting our analysis. This
analysis was done using a cohort of patients
self-selected to participate in SPIROMICS
and therefore may bias toward more severe
and symptomatic groups, decreasing
generalizability to the COPD population as a
whole. Despite these limitations, the robust
and standardized data collection within a
large COPD cohort representing the full
spectrum of COPD provides a unique
opportunity to assess integration of
published COPD treatment strategies over
time and explore factors related to failure to
align with those recommendations. These
findings highlight the possibility of
implementation sciences to improve
guideline adherence in COPD treatment.
In conclusion, this analysis
demonstrates that nearly half of individuals
with COPD participating in an
observational cohort study reported inhaler
regimens not aligning with available
treatment recommendations. Overuse
and underuse of COPD treatment were
equally prevalent and persisted over time,
highlighting the need to reassess patient-
tailored treatment strategies regularly.
Given the changing landscape of classifying
and treating patients with COPD,
improvement of dissemination and uptake
of published recommendations have the
potential to improve care for patients with
COPD. n
Author disclosures are available with the text
of this article at www.atsjournals.org.
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Figure 3. Change in alignment with first- or second-line Global Initiative for Chronic Obstructive Lung
Disease (GOLD) recommendations over follow-up visits among 431 SPIROMICS (Subpopulations and
Intermediate Outcome Measures in COPD Study) participants with complete follow-up data.
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